The U.S. Food and Drug Administration (FDA) announced on 2026-07-01 that the prescribing information for Adalimumab (Yuflyma) will include a new boxed warning. This significant label revision highlights increased risks of serious infections and malignancy associated with the use of the drug.
Background
Adalimumab, known by various brand names and biosimilars including Yuflyma, is a widely prescribed biologic medication. It is a tumor necrosis factor (TNF) blocker, a class of drugs used to treat a range of autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. As a biosimilar to Humira, Yuflyma offers an alternative treatment option for patients requiring TNF inhibition. The safety profile of TNF blockers is well-established, and the FDA continuously monitors and updates prescribing information as new data or risk assessments emerge.
What this means
The implementation of a boxed warning on the Adalimumab (Yuflyma) label is a significant regulatory action by the FDA, effective July 1, 2026. Boxed warnings, often referred to as 'black box warnings,' represent the highest level of warning that the FDA can mandate for prescription drugs. They are reserved for medications that carry serious risks that may lead to death or serious injury. For Yuflyma, this warning specifically highlights the increased risk of serious infections, which can necessitate hospitalization, and the potential for malignancy. These risks are inherent to the mechanism of action of TNF blockers, which modulate the immune system. Healthcare professionals are advised to carefully evaluate patients for active or latent infections before initiating therapy and to monitor them closely during treatment. The warning also prompts consideration of the patient's risk factors for developing malignancies. This update ensures that clinicians, researchers, and patient advocates are fully informed of these critical safety considerations when prescribing, studying, or discussing Yuflyma, reinforcing the importance of a thorough risk-benefit assessment for each individual patient.
Source
This label revision was announced by the FDA on 2026-07-01. The full prescribing information, including the complete boxed warning, is available on dailymed.nlm.nih.gov.